Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nilsa C Ramirez

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2017
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group StudyBarbara M Norquist, Mark F Brady, Maria I Harrell, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 17, 2012
Uterine serous carcinoma: increased familial risk for lynch-associated malignanciesSummer B Dewdney, Nora T Kizer, Abegail A Andaya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2022
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH TrialOlive S Eckstein, Carl E Allen, P Mickey Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2022
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH TrialD Williams Parsons, Katherine A Janeway, David R Patton, et al.
Gynecologic Oncology|November 15, 2017
An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancerCasey M Cosgrove, David L Tritchler, David E Cohn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology GroupFlorette K Hazard, Angus M S Toland, Serena Y Tan, et al.
The Oncologist|May 30, 2024
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trialJulia L Glade Bender, Kerice Pinkney, Paul M Williams, et al.
Journal of the National Cancer Institute|May 25, 2023
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621CSusan N Chi, Joanna S Yi, P Mickey Williams, et al.
The Oncologist|June 14, 2024
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm GMarie V Nelson, AeRang Kim, P Mickey Williams, et al.
JCO Precision Oncology|October 30, 2025
Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH TrialSarah Scollon, Sharon E Plon, Steven Joffe, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2017
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group StudyBarbara M Norquist, Mark F Brady, Maria I Harrell, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 17, 2012
Uterine serous carcinoma: increased familial risk for lynch-associated malignanciesSummer B Dewdney, Nora T Kizer, Abegail A Andaya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2022
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH TrialOlive S Eckstein, Carl E Allen, P Mickey Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2022
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH TrialD Williams Parsons, Katherine A Janeway, David R Patton, et al.
Gynecologic Oncology|November 15, 2017
An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancerCasey M Cosgrove, David L Tritchler, David E Cohn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology GroupFlorette K Hazard, Angus M S Toland, Serena Y Tan, et al.
The Oncologist|May 30, 2024
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trialJulia L Glade Bender, Kerice Pinkney, Paul M Williams, et al.
Journal of the National Cancer Institute|May 25, 2023
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621CSusan N Chi, Joanna S Yi, P Mickey Williams, et al.
The Oncologist|June 14, 2024
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm GMarie V Nelson, AeRang Kim, P Mickey Williams, et al.
JCO Precision Oncology|October 30, 2025
Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH TrialSarah Scollon, Sharon E Plon, Steven Joffe, et al.
Pageof 5